Short answer
DaVita (DVA) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3.6B (up 4.6% year over year) with net income of $223M.
Q3 2026 key financials · XBRL
- Revenue
- $3.6B
- +4.6% YoY · +0.7% QoQ
- Net income
- $223M
- +48.3% YoY · −16.0% QoQ
- Operating margin
- 14.0%
- EPS (diluted)
- $3.41
- +66.3% YoY · −14.5% QoQ
Source: XBRL data from the DaVita (DVA) Q3 2026 10-Q on SEC EDGAR. USD.
DaVita Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Nine-month revenue $10.548B, up 5.2% YoY from $10.023B
- U.S. dialysis revenue $9.004B, up 3.3% YoY, strongest segment
- Operating income $1.560B, up 5.2% YoY from $1.483B, operating margin figures not provided
- Operating cash flow $1.330B vs $1.346B YoY, share repurchases $870M for 5.837M shares
- Headwinds: commercial mix pressure, rising labor and supply costs, policy uncertainty, China impairment charges of $62M
Risk Factors
- No material changes to risk factors disclosed in the 2025 10-K
- Carried-forward risk: forward-looking statements in quarterly Management’s Discussion and Analysis
- Carried-forward risk: risks detailed in the 2025 10-K remain applicable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other DaVita quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.